Valneva (NASDAQ:VALN) Issues Earnings Results

Key Points

• Valneva reported a quarterly earnings per share (EPS) of ($0.16), surpassing analysts' estimates by $0.11.
• The company has a market capitalization of $788.95 million and its shares opened at $9.27.
• Recent analyst ratings include Guggenheim lowering its price target from $15.00 to $14.00 while HC Wainwright maintained a "buy" rating with a $17.00 price target.

Valneva (NASDAQ:VALN - Get Free Report) released its earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11, Zacks reports. The firm had revenue of $54.84 million during the quarter, compared to analyst estimates of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%.

Valneva Trading Up 10.1%

VALN stock traded up $1.06 during trading on Friday, hitting $11.53. The company had a trading volume of 107,741 shares, compared to its average volume of 91,623. The firm has a market capitalization of $981.09 million, a P/E ratio of -11.77 and a beta of 1.77. Valneva has a 52-week low of $3.62 and a 52-week high of $11.53. The company has a 50 day simple moving average of $6.86 and a 200-day simple moving average of $6.75. The company has a quick ratio of 2.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.66.

Analyst Upgrades and Downgrades

Separately, Guggenheim reduced their price target on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.